Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION: Clinical data exist only for baclofen and mostly for alcohol use disorders. Additional trials are needed, but effects are promising. Whether PAMs, given alone or in combination with a direct GABA(B) receptor agonist, will be clinically effective and have fewer side effects requires investigation. The sedative effects of baclofen, a Food and Drug Administration (FDA)-approved drug, become less severe over time. Based on existing data, baclofen is well-tolerated. However, genetic and physiological differences are likely to contribute to individual responses to different therapeutic agents. The more immediate development of baclofen as a therapeutic for alcohol use disorders may be of significant benefit to some individuals.
|
Authors | Tamara J Phillips, Cheryl Reed |
Journal | Expert opinion on drug discovery
(Expert Opin Drug Discov)
Vol. 9
Issue 11
Pg. 1307-17
(Nov 2014)
ISSN: 1746-045X [Electronic] England |
PMID | 25195620
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S., Review)
|
Chemical References |
- Receptors, GABA-B
- Baclofen
|
Topics |
- Animals
- Baclofen
(pharmacology)
- Drug Discovery
- Humans
- Receptors, GABA-B
(metabolism)
- Substance-Related Disorders
(drug therapy, metabolism)
|